Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK1 | Q13464 | 1/20 | 0.38 |
| ▸ | GALR2 | O43603 | 5/20 | 0.38 |
| ▸ | GALR1 | P47211 | 3/20 | 0.38 |
| ▸ | BMI1 | P35226 | 2/20 | 0.38 |
| ▸ | CYP11B1 | P15538 | 5/20 | 0.34 |
| ▸ | CYP11B2 | P19099 | 5/20 | 0.34 |
| ▸ | MAT2A | P31153 | 1/20 | 0.33 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.33 |
| ▸ | JAK2 | O60674 | 1/20 | 0.32 |
| ▸ | JAK1 | P23458 | 1/20 | 0.32 |
| ▸ | MCHR1 | Q99705 | 3/20 | 0.32 |
| ▸ | AGPAT2 | O15120 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16740101 | 0.89 | ROCK2 (0.32) | GALR2GALR1CYP11B1CYP11B2CYP19A1 | |
| SCHEMBL16740324 | 0.88 | CYP11B2 (0.41) | ROCK1GALR2GALR1BMI1CYP11B1 | |
| SCHEMBL16740081 | 0.88 | MCHR1 (0.42) | GALR2GALR1CYP11B1CYP11B2MCHR1 | |
| SCHEMBL16740253 | 0.86 | BMI1 (0.42) | ROCK1GALR2GALR1BMI1CYP11B1 | |
| SCHEMBL16740216 | 0.85 | MCHR1 (0.41) | BMI1CYP11B1CYP11B2MCHR1AGPAT2 | |
| SCHEMBL16740325 | 0.81 | CYP11B1 (0.35) | CYP11B1CYP11B2CYP19A1JAK2JAK1 | |
| SCHEMBL16740289 | 0.77 | CYP11B2 (0.39) | GALR2GALR1CYP11B1CYP11B2CYP19A1 | |
| SCHEMBL18094395 | 0.77 | SCN9A (0.34) | GALR2GALR1CYP11B1CYP11B2CYP19A1 | |
| SCHEMBL16540805 | 0.76 | CYP11B1 (0.32) | CYP11B1CYP11B2CYP19A1MCHR1AGPAT2 | |
| SCHEMBL16740061 | 0.76 | CYP11B2 (0.38) | CYP11B1CYP11B2CYP19A1MCHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160280685-A1 | SUBSTITUTED PYRIDINE AND PYRAZINE BMI-1 INHIBITORS | PTC THERAPEUTICS, INC. | 2016-09-29 | — | — | US | claimed |
| EP-3071553-A1 | SUBSTITUTED PYRIDINE AND PYRAZINE BMI-1 INHIBITORS | PTC Therapeutics, Inc. (US) | 2016-09-28 | — | — | EP | claimed |
| WO-2015076800-A1 | SUBSTITUTED PYRIDINE AND PYRAZINE BMI-1 INHIBITORS | PTC THERAPEUTICS, INC. (US) | 2015-05-28 | — | — | WO | claimed |
| US-10584115-B2 | Substituted pyridine and pyrazine BMI-1 inhibitors | PTC THERAPEUTICS, INC. (US) | 2020-03-10 | — | — | US | disclosed |
| US-20160280685-A1 | SUBSTITUTED PYRIDINE AND PYRAZINE BMI-1 INHIBITORS | PTC THERAPEUTICS, INC. | 2016-09-29 | — | — | US | disclosed |
| US-20160280685-A1 | SUBSTITUTED PYRIDINE AND PYRAZINE BMI-1 INHIBITORS | PTC THERAPEUTICS, INC. | 2016-09-29 | — | — | US | disclosed |
| US-20160280685-A1 | SUBSTITUTED PYRIDINE AND PYRAZINE BMI-1 INHIBITORS | PTC THERAPEUTICS, INC. | 2016-09-29 | — | — | US | disclosed |
| WO-2015076800-A1 | SUBSTITUTED PYRIDINE AND PYRAZINE BMI-1 INHIBITORS | PTC THERAPEUTICS, INC. (US) | 2015-05-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160280685-A1 | SUBSTITUTED PYRIDINE AND PYRAZINE BMI-1 INHIBITORS | BMI1, BAZ2A, BAZ2B | ROCK1 2769/4885GALR2 4615/4885GALR1 4068/4885 |
| US-10584115-B2 | Substituted pyridine and pyrazine BMI-1 inhibitors | BMI1, BAZ2A, BAZ2B | ROCK1 2769/4885GALR2 4615/4885GALR1 4068/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.